Company news

Iovance Biotherapeutics, Inc. news in 2024

Iovance Biotherapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

November 25, 2024

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

November 6, 2024

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

August 7, 2024

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

June 27, 2024

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

May 22, 2024

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

May 8, 2024

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

March 3, 2024

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

February 27, 2024

Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock

February 19, 2024

Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

February 15, 2024

Calls in 2024

Decks in 2024